BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 23208836)

  • 1. Antiangiogenic therapy for cancer: an update.
    Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
    Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
    Girard N
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent concepts of antiangiogenic therapy.
    Konno H; Yamamoto M; Ohta M
    Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab (Avastin).
    Mukherji SK
    AJNR Am J Neuroradiol; 2010 Feb; 31(2):235-6. PubMed ID: 20037132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia.
    Peng F; Chen M
    Chin J Cancer; 2010 Aug; 29(8):715-20. PubMed ID: 20663317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis revisited: Regulators and clinical implications.
    Ronca R; Benkheil M; Mitola S; Struyf S; Liekens S
    Med Res Rev; 2017 Nov; 37(6):1231-1274. PubMed ID: 28643862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
    Weiss A; van Beijnum JR; Bonvin D; Jichlinski P; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    J Cell Mol Med; 2014 Mar; 18(3):480-91. PubMed ID: 24450440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic agents: fueling cancer's hypoxic roots.
    Conley SJ; Wicha MS
    Cell Cycle; 2012 Apr; 11(7):1265-6. PubMed ID: 22421155
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab antiangiogenic therapy for glioblastoma.
    Junck L
    Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    Quesada AR; Medina MA; Alba E
    Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Sessa C; Guibal A; Del Conte G; Rüegg C
    Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of angiogenesis in cancers.
    Pang RW; Poon RT
    Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.